The JDRF T1D Fund announced the expansion of its investment team with the addition of Steven St. Peter, M.D., as a Managing Director. Dr. St. Peter will work alongside Executive Chairman Sean Doherty and Managing Director Katie Ellias to advance and broaden the T1D Fund’s capabilities and expertise in a leadership role on the 11-person fund team.
Dr. St. Peter wants to catalyze faster development of treatments for the autoimmune pancreatic disease. St. Peter, who operated Vie Ventures, also was a managing director at MPM Capital, says one focus will be to help existing biopharma companies pivot part of their pipeline toward type 1 diabetes.
The JDRF T1D Fund’s aim is to create a new investment market aimed at delivering solutions to those living with or at risk of developing T1D. Launched in December 2016, the T1D Fund is a combination of venture capital and philanthropy focused solely on T1D. The portfolio consists of therapeutics, devices, vaccines, and diagnostics.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. The organization’s strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF and the T1D Fund are two separate entities, run by separate teams, following separate volunteer governance, and each with a different approach to opportunities.
The JDRF T1D Fund recently invested in ImmunoMolecular Therapeutics to leverage new insights around autoimmune biology and the fund’s growing capital base to expand the scope of the fund.